Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
1 g IV every 8 hours infused over 15-30 minutes; dose range 0.5-2 g every 8 hours depending on infection severity
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
1.0–1.5 hours in healthy adults; prolonged to 4–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and 8–12 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: ~70% unchanged via glomerular filtration and tubular secretion; hepatic metabolism: ~20% via hydrolysis of beta-lactam ring; fecal: <2%.
Category C
Category A/B
Electrolyte
Electrolyte